Bhinneka News Online: Reuters Health Report: June 13, 2017

Tuesday, 13 June 2017

Reuters Health Report: June 13, 2017

Click to View in Browser

Tuesday, June 13, 2017

Supreme Court speeds copycat biologic drugs to market

WASHINGTON (Reuters) - The U.S. Supreme Court on Monday cut the time it will take for copycat versions of biologic drugs to get to the market in a pivotal ruling about an expensive class of medicines that can yield billions of dollars in sales for drug companies.

J&J diabetes drug shows heart benefit in large safety study

(Reuters) - Johnson & Johnson's type 2 diabetes drug Invokana significantly reduced the risk of serious heart problems in patients with established heart disease or at elevated risk in a pair of large studies, according to data presented at a medical meeting on Monday.

Merck to pause two late-stage studies testing Keytruda in myeloma

(Reuters) - Merck & Co said it paused enrolments in two late-stage studies testing its immunotherapy drug, Keytruda, for multiple myeloma, in combination with other therapies, as the U.S. drugmaker looks to better understand more reports of death in the Keytruda groups.

Bayer, J&J win second U.S. trial over Xarelto bleeding risks

(Reuters) - A federal jury has cleared Bayer AG and Johnson & Johnson of liability in the second trial to stem from thousands of lawsuits blaming injuries on the blood thinner Xarelto, the drug companies said on Monday.

ISS pressures Mylan ahead of shareholder vote

(Reuters) - Influential proxy firm ISS on Monday turned up the heat on Mylan NV, advising its institutional clients to voice their dissatisfaction with the generic drugmaker's board of directors and its chairman's pay package at its June 22 shareholder meeting.

Drug reduces dyskinesia, 'off' times in Parkinson's patients

(Reuters Health) - An experimental extended-release version of the drug amantadine can reduce the duration of the involuntary dancing-like movements seen in people whose long-term use of levodopa has kept their Parkinson's disease under control.

ADHD tied to driver's license delays, crash risks

(Reuters Health) - Adolescents with attention deficit hyperactivity disorder (ADHD) may wait longer than other teens to obtain a driver's license, and they may be at higher risk for accidents once they do start driving, suggests a new study.

Jury quirk in U.S. meningitis outbreak case could bring stiffer sentence

BOSTON (Reuters) - Prosecutors on Monday said a quirk in the trial verdict of a Massachusetts pharmacist cleared of murder for selling fungus-ridden steroids that killed 64 people in 2012 meant that a judge could still consider the murder allegations at his sentencing.

What's in a name? Maybe a more appealing vegetable

(Reuters Health) - People may be more likely to pile vegetables on their plates when these dishes are served up with seductive names like "sweet sizzlin' green beans and crispy shallots" than when they're peddled as health foods, a recent experiment suggests.

Missouri sued for over-exposing foster children to psychotropic drugs

(Reuters) - Two youth legal advocacy groups sued Missouri on Monday on behalf of 13,000 foster children, arguing that poor oversight left many of them over-exposed to psychotropic drugs carrying risks of side effects, from diabetes to seizures.